Drug Trial Radar · NCT00455195
Late-Onset Treatment Study Extension Protocol
Last checked: Nov 20, 2026Latest source record: Mar 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Mar 2007
Primary completion
Oct 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this extension study is to assess the long-term safety and efficacy of alglucosidase alfa treatment in patients with Late-Onset Pompe Disease who were previously treated under the placebo-controlled, double-blind study AGLU02704 (NCT00158600).
Conditions
- Pompe Disease (Late-Onset)
- Glycogen Storage Disease Type II (GSD-II)
- Glycogenesis Type II
- Acid Maltase Deficiency (AMD)
Interventions
alglucosidase alfaBiological
IV infusion of 20 mg/kg; every other week (qow)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0 to 2.5 years
- Baseline Values (Week 0) of Functional Endurance as Measured by Six-Minute Walk Test (6MWT) For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0
- Change From Baseline (Week 0) in the Six-Minute Walk Test (6MWT) at Week 104 For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0, Week 104
- Baseline Values (Week 0) for Percent Predicted Forced Vital Capacity (FVC) For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0
- Change From Baseline (Week 0) in the Percent Predicted Forced Vital Capacity (FVC) at Week 104 For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0, Week 104
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Anchorage, Alaska
Site not named
Phoenix, Arizona
Site not named
Beverly Hills, California
Site not named
San Diego, California
Site not named
Washington D.C., District of Columbia
Site not named
Coral Springs, Florida
Site not named
Gainesville, Florida
Site not named
Sarasota, Florida
Site not named
Chicago, Illinois
Site not named
Kansas City, Kansas
Site not named
New Orleans, Louisiana
Site not named
Boston, Massachusetts
Site not named
Omaha, Nebraska
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Toledo, Ohio
Site not named
Tulsa, Oklahoma
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Seattle, Washington
Site not named
Green Bay, Wisconsin
Site not named
Westmead, Australia
Site not named
Calgary, Alberta, Canada
Site not named
Sherbrooke, Quebec, Canada
Site not named
Paris, France
Site not named
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.